Literature DB >> 23896090

Addition of antimuscarinics to alpha-blockers for treatment of lower urinary tract symptoms in men: a meta-analysis.

Zhixiang Xin1, Yiran Huang, Jun Lu, Qi Zhang, Chen Chen.   

Abstract

Alpha-blockers and antimuscarinics combination therapy has been commonly used for treatment of male lower urinary tract symptoms (LUTS). We conducted a meta-analysis aimed to access the relative efficacy and safety of combination therapy. We systematically searched Medline, Cochrane, and Embase for eligible studies. Fifteen randomized studies with 4556 patients were included. Overall, combination therapy significantly improved the urgency, voiding frequency, International Prostate Symptom Score (IPSS) total scores, and IPSS storage subscores. Addition of antimuscarinics had little effect on urinary function. The incidences of adverse events were acceptably low. Our meta-analysis demonstrated that the combination therapy was a safe, well-tolerated, and effective treatment for male LUTS.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23896090     DOI: 10.1016/j.urology.2013.04.045

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  3 in total

1.  Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction.

Authors:  Ran Pang; Xin-Yao Zhou; Xiangling Wang; Bin Wang; Xue-Lai Yin; Hai Bo; Jae Hung Jung
Journal:  Cochrane Database Syst Rev       Date:  2021-02-10

2.  Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial.

Authors:  Yu Seob Shin; Li Tao Zhang; Jae Hyung You; In Sung Choi; Chen Zhao; Jong Kwan Park
Journal:  Clin Interv Aging       Date:  2016-09-19       Impact factor: 4.458

3.  Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia.

Authors:  Antoni Sicras-Mainar; Ruth Navarro-Artieda; Ana Mª Mora; Marta Hernández
Journal:  BMC Urol       Date:  2017-09-12       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.